A study conducted by P&G Health, the healthcare division of The Procter & Gamble Company, has found that its nasal mucoadhesive gel technology could reduce SARS-CoV-2 coronavirus infection of cells.

The company’s nasal mucoadhesive gel technology works as an intranasal spray. It was originally intended for use against common cold viruses.

A standard antiviral laboratory test was carried out by the research team at the P&G Health to assess the technology’s ability to prevent the SARS-CoV-2 virus from infecting cells it needs for replication.

During the test, the nasal mucoadhesive gel formulation was combined with the virus for one, five, and ten minutes. These mixtures were added to cell monolayers and virus quantity was then assessed from the cells after a seven-day incubation.

It was found that the nasal mucoadhesive gel reduced the level of SARS-CoV-2 viruses by 99.5% at one-minute exposure. The test showed greater reductions with five and ten minutes of exposure.

According to the company, this suggests the nasal mucoadhesive gel may reduce SARS-CoV-2 virus infection of cells.

However, it noted that further clinical research is required to confirm whether the technology can offer a protective benefit against SARS-CoV-2 in humans.

P&G Health is currently evaluating a number of research proposals to evaluate the efficacy of the nasal mucoadhesive gel against a number of respiratory viruses, including SARS-CoV-2.

The nasal mucoadhesive gel is currently used in Vicks First Defence intranasal spray, which is a medical device in Europe approved for use against common cold viruses.